CD300A inhibits tumor cell growth by downregulating AKT phosphorylation in human glioblastoma multiforme

Xinrui Du1,2, Bin Liu3, Qian Ding4

  • 1Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong University Jinan, China.

Insights

CD300A is overexpressed in glioblastoma multiforme (GBM) and acts as an oncogene. Inhibiting CD300A blocks GBM cell growth and migration, offering a potential therapeutic target for this aggressive brain tumor.

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Immunology

Background:

  • Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with poor outcomes.
  • The CD300 glycoprotein family member, CD300A, influences cell functions but its role in solid tumors is unclear.

Purpose of the Study:

  • To investigate the role and mechanism of CD300A in glioblastoma multiforme (GBM).

Main Methods:

  • Real-time PCR and western blotting to assess CD300A expression in GBM samples.
  • Cell proliferation (CCK8), migration (Transwell), and apoptosis (flow cytometry) assays in GBM cell lines (U251MG, U87MG).
  • Analysis of AKT pathway activation in CD300A knockdown cells.

Main Results:

  • CD300A was significantly overexpressed in human GBM tissues.
  • Knockdown of CD300A inhibited proliferation and migration while inducing apoptosis in GBM cells.
  • CD300A knockdown suppressed AKT phosphorylation, indicating involvement of the AKT pathway.

Conclusions:

  • CD300A functions as an oncogene in GBM, promoting tumor cell growth and survival.
  • Targeting CD300A may represent a novel therapeutic strategy for glioblastoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K